|
|
|
| The research progress of FAPI PET/CT in the diagnosis of gastrointestinal tumors |
| JIN Jingguo, WANG Zhiqiang, SUN Weijun, XU Hui, ZHANG Wanle. |
| Department of Nuclear Medicine, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325015, China |
|
| Cite this article: |
|
JIN Jingguo,WANG Zhiqiang,SUN Weijun, et al. The research progress of FAPI PET/CT in the diagnosis of gastrointestinal tumors[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2024, 54(2): 158-164.
|
|
|
|
Abstract Nuclear medicine radiopharmaceuticals is a type of compound labeled with radioisotopes as a tool for imaging and treatment of specific biology or organs. Isotope labeled fibroblast activation protein inhibitor (FAPI) is a new type of radiopharmaceutical with high sensitivity and specificity, capable of providing highresolution images, accurately detecting and locating tumors, evaluating their growth and metastasis, and detecting therapeutic effects. Widely studied and used in the diagnosis and treatment of various cancers, it can provide detailed information about tumor tissues and help to develop treatment plan for the individuals. In this review, we will introduce the characteristics of FAPI and its application in gastrointestinal tumors, and compare its advantages and disadvantages with 18F-FDG PET/CT in cancer diagnosis to further illustrate the clinical value of FAPI in gastrointestinal tumors.
|
|
Received: 06 July 2023
|
| |
|
|
|
|
|
|
